Published in Arch Intern Med on July 14, 2003
The Marigot Osteoarthritis Nutritional Intervention (MOANi) Trial (MOANi) | NCT03106584
The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum (2008) 2.37
Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. Arthritis Res Ther (2006) 1.53
Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis (2010) 1.51
Use of complementary therapies among primary care clinic patients with arthritis. Prev Chronic Dis (2004) 1.44
Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol (2010) 1.33
Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis (2007) 1.16
Total mortality risk in relation to use of less-common dietary supplements. Am J Clin Nutr (2010) 1.15
Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis (2005) 1.14
Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int (2009) 1.11
Carbohydrate engineered cells for regenerative medicine. Adv Drug Deliv Rev (2010) 1.04
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord (2008) 1.04
Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res Ther (2012) 1.03
Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Res Ther (2007) 0.97
The continuing story of nutritional supplements and doping infractions. Br J Sports Med (2007) 0.96
Chondroprotective Potential of Fruit Extracts of Phyllanthus emblica in Osteoarthritis. Evid Based Complement Alternat Med (2008) 0.95
Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids. Int J Rheumatol (2011) 0.95
Chondroprotective activity of N-acetylglucosamine in rabbits with experimental osteoarthritis. Ann Rheum Dis (2005) 0.94
Chondroitin for osteoarthritis. Cochrane Database Syst Rev (2015) 0.94
The Hip and Knee Book: developing an active management booklet for hip and knee osteoarthritis. Br J Gen Pract (2010) 0.90
Immunological activity of chondroitin sulfate. Adv Pharmacol (2006) 0.87
Efficacy of a progressive walking program and glucosamine sulphate supplementation on osteoarthritic symptoms of the hip and knee: a feasibility trial. Arthritis Res Ther (2010) 0.87
Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Res Ther (2012) 0.86
Glucosamine supplementation demonstrates a negative effect on intervertebral disc matrix in an animal model of disc degeneration. Spine (Phila Pa 1976) (2013) 0.85
Role of glucosamine in the treatment for osteoarthritis. Rheumatol Int (2012) 0.85
Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Ther Adv Musculoskelet Dis (2010) 0.85
Comparison of glucose derivatives effects on cartilage degradation. BMC Musculoskelet Disord (2010) 0.81
Predictors of symptomatic response to glucosamine in knee osteoarthritis: an exploratory study. Br J Sports Med (2007) 0.81
Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older. PLoS One (2012) 0.81
Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled pilot study using MRI. Clin Rheumatol (2012) 0.81
The effects of glucosamine sulfate on intervertebral disc annulus fibrosus cells in vitro. Spine J (2013) 0.80
Effect of a glucosamine-based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: A pilot study. Exp Ther Med (2011) 0.80
Current evidence for osteoarthritis treatments. Ther Adv Musculoskelet Dis (2010) 0.80
Experimental pharmacology of glucosamine sulfate. Int J Rheumatol (2011) 0.80
A clinical study on glucosamine sulfate versus combination of glucosamine sulfate and NSAIDs in mild to moderate knee osteoarthritis. ScientificWorldJournal (2012) 0.80
Effects of glucosamine and risedronate alone or in combination in an experimental rabbit model of osteoarthritis. BMC Vet Res (2014) 0.78
Bone resorption and remodeling in murine collagenase-induced osteoarthritis after administration of glucosamine. Arthritis Res Ther (2011) 0.78
Changes in serum levels of glucosamine and sulphate after ingestion of glucosamine sulphate with and without simultaneous ingestion of glucose. Ann Rheum Dis (2007) 0.78
Effect of the herbal drug guilu erxian jiao on muscle strength, articular pain, and disability in elderly men with knee osteoarthritis. Evid Based Complement Alternat Med (2014) 0.78
Combined glucosamine and chondroitin sulfate, once or three times daily, provides clinically relevant analgesia in knee osteoarthritis. Clin Rheumatol (2014) 0.77
Combined glucosamine and chondroitin sulfate provides functional and structural benefit in the anterior cruciate ligament transection model. Clin Rheumatol (2008) 0.76
Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. Open Rheumatol J (2013) 0.76
Intra-articular delivery of chondroitin sulfate for the treatment of joint defects in rabbit model. J Mol Histol (2007) 0.76
A randomized comparative study of safety and efficacy of immediate release glucosamine HCL and glucosamine HCL sustained release formulation in the treatment of knee osteoarthritis: A proof of concept study. J Pharmacol Pharmacother (2012) 0.76
Glucosamine and chondroitin effective for knee osteoarthritis. J Fam Pract (2003) 0.76
DRUG THERAPY IN KNEE OSTEOARTHROSIS. Rev Bras Ortop (2015) 0.75
Osteoarthritis of the knee. BMJ Clin Evid (2007) 0.75
Structural and symptomatic efficacy of glucosamine and chondroitin: relevant financial interest? Arch Intern Med (2004) 0.75
Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther (2016) 0.75
Efficacy of glucosamine, chondroitin, and methylsulfonylmethane for spinal degenerative joint disease and degenerative disc disease: a systematic review. J Can Chiropr Assoc (2011) 0.75
Effect of glucosamine on intraocular pressure: a randomized clinical trial. Eye (Lond) (2016) 0.75
Glucosamine and chondroitin for the treatment of osteoarthritis. World J Orthop (2017) 0.75
Amelioration of collagen-induced arthritis in female dark agouti rats by glucosamine treatment. ISRN Pharmacol (2013) 0.75
[Evidence-based evaluation of study results of symptomatic glucosamine therapy]. Z Rheumatol (2005) 0.75
Digital X-ray radiogrammetry better identifies osteoarthritis patients with a low bone mineral density than quantitative ultrasound. Eur Radiol (2006) 0.75
[Non-surgical treatment of osteoarthritis of large joints - new aspects]. Wien Med Wochenschr (2009) 0.75
Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am (2004) 7.59
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med (2006) 4.46
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res (2004) 2.67
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma (2008) 2.28
Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med (2006) 2.28
Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol (2011) 2.25
Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia (2007) 2.13
Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. J Rheumatol (2003) 1.85
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med (2012) 1.85
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 1.82
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol (2011) 1.68
The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum (2007) 1.65
Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr Med Res Opin (2012) 1.64
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab (2013) 1.60
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause (2004) 1.57
Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.54
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Strategies for the prevention of hip fracture. Am J Med (2003) 1.50
Compliance-guided therapy : a new insight into the potential role of clinical pharmacologists. Clin Pharmacokinet (2006) 1.50
Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med (2008) 1.48
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. Bone (2008) 1.48
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (2008) 1.44
Controlled whole body vibration to decrease fall risk and improve health-related quality of life of nursing home residents. Arch Phys Med Rehabil (2005) 1.42
Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int (2005) 1.36
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab (2007) 1.32
Pooling, meta-analysis, and the evaluation of drug safety. Curr Control Trials Cardiovasc Med (2002) 1.29
Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia (2011) 1.27
Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am (2008) 1.27
Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage (2004) 1.25
Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res (2006) 1.20
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol (2008) 1.18
Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res (2003) 1.17
Quality of life in sarcopenia and frailty. Calcif Tissue Int (2013) 1.17
Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol (2011) 1.15
Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol (2007) 1.15
The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab (2014) 1.14
Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Prefer Adherence (2013) 1.11
Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Res Ther (2014) 1.11
Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother (2009) 1.10
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab (2012) 1.09
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res (2010) 1.08
Osteoarthritis and obesity: experimental models. Joint Bone Spine (2008) 1.07
Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging (2007) 1.07
Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone (2007) 1.06
Perioperative outcome and long-term survival of surgery for acute post-infarction mitral regurgitation. Eur J Cardiothorac Surg (2004) 1.06
New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage (2005) 1.06
D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clin Exp Res (2005) 1.06
Performance of osteoporosis risk assessment tools in postmenopausal women aged 45-64 years. Osteoporos Int (2004) 1.05
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord (2008) 1.04
Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol (2004) 1.03
Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol (2002) 1.02
The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis. J Rheumatol (2002) 1.02
Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int (2004) 1.01
Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation. Eur J Clin Pharmacol (2004) 1.01
Development of a clinical assessment tool in identifying Asian men with low bone mineral density and comparison of its usefulness to quantitative bone ultrasound. Osteoporos Int (2004) 1.00
Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol (2006) 0.99
Gene expression pattern of cells from inflamed and normal areas of osteoarthritis synovial membrane. Arthritis Rheumatol (2014) 0.99
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int (2005) 0.99
New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear. J Clin Epidemiol (2007) 0.98
Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clin Exp Res (2007) 0.98
Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin (2006) 0.97
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol (2008) 0.97
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin (2008) 0.96
Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics (2011) 0.96
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res (2004) 0.96
Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum (2013) 0.95
A systematic review of the accuracy of ultrasound in the diagnosis of deep venous thrombosis in asymptomatic patients. Thromb Haemost (2004) 0.95
Runx2- and histone deacetylase 3-mediated repression is relieved in differentiating human osteoblast cells to allow high bone sialoprotein expression. J Biol Chem (2007) 0.95
The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy (2010) 0.95
Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int (2008) 0.94
Osteochondral plate angiogenesis: a new treatment target in osteoarthritis. Joint Bone Spine (2010) 0.94
The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health (2012) 0.93
Age- and sex-stratified prevalence of physical disabilities and handicap in the general population. Aging Clin Exp Res (2004) 0.93
Birth simulator: reliability of transvaginal assessment of fetal head station as defined by the American College of Obstetricians and Gynecologists classification. Am J Obstet Gynecol (2005) 0.92
Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health (2011) 0.92
High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunol Immunother (2008) 0.92
Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res (2008) 0.92
Early effect of hyaluronic acid intra-articular injections on serum and urine biomarkers in patients with knee osteoarthritis: An open-label observational prospective study. J Orthop Res (2011) 0.92
Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. Calcif Tissue Int (2010) 0.92
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin (2003) 0.92
Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone (2008) 0.91